ロード中...
Ruxolitinib inhibits IFNγ licensing of human bone marrow derived Mesenchymal Stromal Cells
BACKGROUND: Ruxolitinib is a JAK2/JAK1 inhibitor which blocks inflammatory JAK-STAT signaling pathway. Ruxolitinib has been demonstrated to be effective in the treatment of steroid-resistant acute Graft vs Host Disease (GvHD). Ruxolitinib’s effect on inflammatory cells of hematopoietic origin is kno...
保存先:
| 出版年: | Transplant Cell Ther |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8110949/ https://ncbi.nlm.nih.gov/pubmed/33965175 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtct.2021.02.002 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|